Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Alterity Therapeutics ADR ATHE

Healthcare Biotechnology
Alterity Therapeutics Limited is an Australia-based clinical-stage biotechnology company. The Company is focused on developing disease modifying treatments for neurodegenerative diseases. The Company's lead asset, ATH434, is to treat various Parkinsonian disorders. ATH434 is an oral agent designed to inhibit the aggregation of pathological proteins implicated in neurodegeneration. It has the... see more

Recent & Breaking News (NDAQ:ATHE)

Alterity Therapeutics to Host Webcast to Discuss ATH434 Efficacy Data in Primates and Recent Clinical Progress

GlobeNewswire December 4, 2023

Alterity Therapeutics Reports Positive Efficacy Data for ATH434 in a Primate Model of Parkinson's Disease

GlobeNewswire December 4, 2023

Alterity Therapeutics Announces Presentation of Novel Biomarker Data for Evaluation of Multiple System Atrophy

GlobeNewswire November 27, 2023

Alterity Therapeutics Announces Presentation of New Data Demonstrating Novel Mechanisms of ATH434

GlobeNewswire November 16, 2023

Alterity Therapeutics Completes Enrolment in ATH434-201 Phase 2 Clinical Trial in Multiple System Atrophy

GlobeNewswire November 8, 2023

Appendix 4C - Q1 FY24 Quarterly Cash Flow Report

GlobeNewswire October 30, 2023

Alterity Therapeutics Presents New Data on Multiple System Atrophy, a Rare Parkinsonian Disorder

GlobeNewswire August 31, 2023

Alterity Therapeutics Granted New Composition of Matter Patent in Europe for Neurodegenerative Diseases including Parkinson's and Alzheimer's

GlobeNewswire August 23, 2023

Alterity Therapeutics Rare Disease Natural History Study to be Featured at the International Congress of Parkinson's Disease and Movement Disorders

GlobeNewswire August 22, 2023

Alterity Therapeutics Receives a $4.74 million Research & Development Tax Incentive Refund

GlobeNewswire August 15, 2023

Appendix 4C - Q4 FY23 Quarterly Cash Flow Report

GlobeNewswire July 31, 2023

Alterity Therapeutics Phase 2 Data Monitoring Committee Recommends Continuing Clinical Trial as Planned

GlobeNewswire July 26, 2023

Alterity Therapeutics to Present in MST Access Rare Diseases, Rich Returns Forum on 22 June 2023

GlobeNewswire June 21, 2023

Alterity Therapeutics Initiates Second Phase 2 Study in Rare Parkinsonian Disorder

GlobeNewswire May 30, 2023

Alterity Therapeutics CEO David Stamler to Present at the SHARE Series Monday Management Update on Monday, May 22, 2023

GlobeNewswire May 19, 2023

Alterity Therapeutics Enrolls First Patient in Australia in ATH434 Global Phase 2 Clinical Trial in Multiple System Atrophy

GlobeNewswire May 10, 2023

Appendix 4C - Q3 FY23 Quarterly Cash Flow Report

GlobeNewswire May 10, 2023

Alterity Therapeutics Presents Promising Wearable Sensor Data from the bioMUSE Natural History Study at the American Academy of Neurology

GlobeNewswire April 26, 2023

Alterity Therapeutics Enrolls First Patient in the United Kingdom in ATH434 Phase 2 Clinical Trial in Multiple System Atrophy

GlobeNewswire April 4, 2023

Alterity Therapeutics Enrolls First Patient in the U.S. in ATH434 Phase 2 Clinical Trial in Multiple System Atrophy

GlobeNewswire March 16, 2023